1Salminen E,Mac Manus M. FDG-PET imaging in the management of non-small-cell lung cancer[J]. Ann Oncol, 2002,13 (3) : 357-360.
2Mcloud TC, Bourgouin PM,Greenburg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling[J]. Radiology,1992,182(2) :319-323.
3Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole body positron emission tomographic imaging[J].Ann Thorac Surg,1995,60(6) :1573-1581.
5Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography~a prospective study[J].J Nucl Med,1990,31(12) :1927-1933.
6Gupta NC,Frank AR,Dewan NA,et al. Solitary pulmonary nodules:detection of malignancy with PET with 2-[F-18]-Fluoro-2-deoxy-D-glucose[J]. Radiology, 1992,184(2) :441-444.
7Graeber GM,Gupta NC,Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease[J]. J Thorac Cardiovasc Surg, 1999,117(4) :719-727.
8Von Haag DW, Follette DM, Roberts PF, et al. Advantages of positron emission tomography in mediastinal staging of non small cell lung cancer[J]. J Surg Res,2002,103(2):160-164.
10Eschmann SM,Friedel G, Paulsen F et al. FDG-PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radiochemotherapy[J]. Eur J Nucl Mol Imaging,2002,29(6) :804-808.
